Meiji Yasuda Life Insurance Co Acquires 7,000 Shares of Edwards Lifesciences Corporation $EW

Meiji Yasuda Life Insurance Co increased its stake in Edwards Lifesciences Corporation (NYSE:EW) by 39.1% during the second quarter, according to its most recent filing with the SEC. The fund owned 24,900 shares of the medical research company’s stock after buying an additional 7,000 shares during the quarter. Meiji Yasuda Life Insurance Co’s holdings in Edwards Lifesciences were worth $2,252,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in EW. Hanson & Doremus Investment Management bought a new position in shares of Edwards Lifesciences during the 1st quarter valued at approximately $25,000. JPL Wealth Management LLC bought a new stake in shares of Edwards Lifesciences in the 3rd quarter worth approximately $25,000. MV Capital Management Inc. purchased a new position in Edwards Lifesciences in the fourth quarter valued at approximately $26,000. RMG Wealth Management LLC purchased a new position in Edwards Lifesciences in the first quarter valued at approximately $26,000. Finally, Pin Oak Investment Advisors Inc. bought a new position in Edwards Lifesciences during the second quarter valued at $26,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insider Transactions at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 619 shares of the business’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total value of $56,966.57. Following the completion of the sale, the vice president owned 40,034 shares in the company, valued at $3,684,329.02. The trade was a 1.52% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Annette Bruls sold 2,644 shares of the company’s stock in a transaction that occurred on Friday, August 28th. The stock was sold at an average price of $89.98, for a total value of $237,907.12. Following the completion of the sale, the vice president directly owned 17,984 shares of the company’s stock, valued at approximately $1,618,200.32. This represents a 12.82% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 4,501 shares of company stock worth $408,213 in the last 90 days. Company insiders own 0.31% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the company. Evercore reissued an “outperform” rating and issued a $100.00 target price on shares of Edwards Lifesciences in a research report on Monday, July 6th. Leerink Partners upgraded Edwards Lifesciences from a “market perform” rating to an “outperform” rating and increased their price target for the stock from $87.00 to $101.00 in a research note on Friday, July 24th. Wall Street Zen cut Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Saturday, July 4th. Piper Sandler reaffirmed an “overweight” rating and set a $101.00 price objective (up from $100.00) on shares of Edwards Lifesciences in a report on Friday, July 24th. Finally, BTIG Research lifted their target price on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the stock a “buy” rating in a research note on Tuesday, June 30th. Seventeen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat.com, Edwards Lifesciences has an average rating of “Moderate Buy” and an average price target of $100.27.

Edwards Lifesciences Stock Performance

NYSE:EW opened at $90.19 on Friday. The stock has a market cap of $51.93 billion, a P/E ratio of 51.83, a PEG ratio of 2.37 and a beta of 0.85. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06. The business’s 50-day moving average price is $89.54 and its two-hundred day moving average price is $85.03. Edwards Lifesciences Corporation has a twelve month low of $72.30 and a twelve month high of $96.29.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The company had revenue of $1.74 billion for the quarter, compared to analysts’ expectations of $1.70 billion. During the same period in the prior year, the business earned $0.67 earnings per share. Edwards Lifesciences’s revenue for the quarter was up 13.6% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, equities analysts predict that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.